Point72 Asset Management L.P. boosted its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 61.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,600,740 shares of the company's stock after purchasing an additional 609,939 shares during the quarter. Point72 Asset Management L.P. owned approximately 2.83% of Design Therapeutics worth $8,612,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Design Therapeutics by 29.0% during the 1st quarter. Vanguard Group Inc. now owns 1,285,962 shares of the company's stock valued at $5,182,000 after acquiring an additional 288,803 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Design Therapeutics during the 1st quarter worth approximately $45,000. Bank of New York Mellon Corp lifted its stake in Design Therapeutics by 2.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 118,110 shares of the company's stock valued at $396,000 after buying an additional 2,868 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Design Therapeutics by 44.5% during the 2nd quarter. Acadian Asset Management LLC now owns 583,160 shares of the company's stock valued at $1,952,000 after buying an additional 179,614 shares during the last quarter. Finally, American Century Companies Inc. acquired a new stake in Design Therapeutics during the 2nd quarter valued at $71,000. Institutional investors and hedge funds own 56.64% of the company's stock.
Design Therapeutics Trading Up 3.7 %
Shares of NASDAQ DSGN traded up $0.23 during trading on Friday, reaching $6.41. The company had a trading volume of 89,437 shares, compared to its average volume of 153,891. Design Therapeutics, Inc. has a twelve month low of $2.24 and a twelve month high of $7.77. The stock has a 50-day moving average price of $5.63 and a two-hundred day moving average price of $4.84. The stock has a market capitalization of $362.93 million, a PE ratio of -7.54 and a beta of 1.86.
Design Therapeutics Company Profile
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Read More
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
